Details of the Drug Combinations

General Information of This Drug (ID: DMYGJQO)

• Drug Name: Ponatinib (DMYGJQO)
• Synonyms: Iclusig (TN)

Indication

Acute lymphoblastic leukaemia; ICD 11: 2A85; Status: Approved [1]; Chronic myelogenous leukaemia; ICD 11: 2A20.0; Status: Approved [2]; Thyroid tumor; ICD 11: N.A.; Status: Approved [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Azacitidine + Ponatinib	DCKOCWP	Azacitidine	Leukemia	[3]
Trametinib + Ponatinib	DCGOTK3	Trametinib	Non Small Cell Lung Cancer	[4]
Aspirin + Ponatinib	DCKCDW7	Aspirin	Chronic Myeloid Leukemia, Chronic Phase	[5]
Azacitidine + Ponatinib	DCFIDQS	Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE	[6]
Imatinib + Ponatinib	DCRZ7C5	Imatinib	Philadelphia Chromosome Positive CML	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5890).
• [2] Ponatinib FDA Label
• [3] ClinicalTrials.gov (NCT02829840) Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
• [4] ClinicalTrials.gov (NCT03704688) Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
• [5] ClinicalTrials.gov (NCT04160546) Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
• [6] ClinicalTrials.gov (NCT03895671) PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
• [7] ClinicalTrials.gov (NCT04070443) Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase